EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Huangkui capsule combined with finerenone attenuates diabetic nephropathy by regulating the JAK2/STAT3 signaling pathway based on network pharmacology, molecular docking, and experimental verification

Xuanke Liu, Chunjiang Zhang, YanJie Fu, JingJing Dai, Jiaying Lu, Gang Liu, Xiaoping Yang

Frontiers in Pharmacology · 04.08.2025 · 16

DOI: 10.3389/fphar.2025.1625286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.08.2025. Verfasst von Xuanke Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The First Affiliated Hospital of Shihezi University, Shihezi, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Diabetic nephropathy (DN) is a serious complication of diabetes with limited therapeutic options. Although Huangkui capsule (HKC) and finerenone individually show potential in DN management, their combined mechanism remains unclear. This study aimed to explore the therapeutic effects and underlying mechanisms of HKC and finerenone combination for DN.

Methods

An integrative approach combining network pharmacology, molecular docking, kinetic simulations, and experimental validation was employed in this study. Active components of HKC and finerenone, along with their potential targets, were identified through database mining. A “drug-component-target-disease” network was constructed, and interactions with the JAK2/STAT3 pathway were validated. In vivo , DN mice were treated with HKC, finerenone, and their combination (CDI group), while in vitro , HK-2 cells were treated with quercetin (a core HKC component) and finerenone. The binding index between quercetin and finerenone was analyzed by using the Chou–Talalay method.

Results

Network pharmacology identified three core HKC components (quercetin, myricetin, and gossypetin) and 11 key targets (e.g., JAK2, STAT3, and AKT1). Molecular docking revealed strong binding affinity between quercetin–finerenone and JAK2/STAT3 (ΔG = −65.465 kcal/mol for STAT3-quercetin). In DN mice, combined therapy significantly reduced 24-h urinary protein (358.54 ± 21.21 mg/L vs. 1046.48 ± 72.84 mg/L in the model group, p < 0.001), improved serum creatinine/urea nitrogen, and downregulated IL-6/TNF-α expression. It also suppressed pro-apoptotic gene ( Bax, Caspase-3/8, and PARP ) activity while upregulating that of Bcl-2. Histopathology showed reduced tubular injury markers (NGAL and KIM-1) and fibrosis (p < 0.05). In HK-2 cells, quercetin + finerenone synergistically inhibited apoptosis and inflammation (p < 0.05), and the combined index (cl) was calculated to be less than 1. STAT3 overexpression exacerbated inflammation/apoptosis, which was reversed by combined treatment (p < 0.01).

Conclusion

HKC combined with finerenone mitigates DN progression by inhibiting the JAK2/STAT3 pathway and reducing inflammation, apoptosis, and tubular injury. These findings provide a mechanistic basis for clinical application of this combination therapy.

Schlagwörter

Stichwörter der Autor:innen

JAK2/STAT3 signaling pathwaydiabetic nephropathyfinerenonekinetic simulationmolecular dockingnetwork pharmacology

Autor:innen und Institutionen

  • Department of Nephrology, The First Affiliated Hospital of Shihezi University, Shihezi, China.

Zitieren

APA

Liu, X., Zhang, C., Fu, Y., Dai, J., Lu, J., Liu, G., & Yang, X. (2025). Huangkui capsule combined with finerenone attenuates diabetic nephropathy by regulating the JAK2/STAT3 signaling pathway based on network pharmacology, molecular docking, and experimental verification. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1625286

Vancouver

Liu X, Zhang C, Fu Y, Dai J, Lu J, Liu G, et al. Huangkui capsule combined with finerenone attenuates diabetic nephropathy by regulating the JAK2/STAT3 signaling pathway based on network pharmacology, molecular docking, and experimental verification. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1625286

BibTeX
@article{Liu2025,
  author = {Liu, Xuanke and Zhang, Chunjiang and Fu, YanJie and Dai, JingJing and Lu, Jiaying and Liu, Gang and Yang, Xiaoping},
  title = {Huangkui capsule combined with finerenone attenuates diabetic nephropathy by regulating the JAK2/STAT3 signaling pathway based on network pharmacology, molecular docking, and experimental verification},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1625286}
}
Kostenlos starten →